Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02270931 · ClinicalTrials.gov registry record

A Prospective Longitudinal Breast Cancer Study

A clinical trial of Breast Cancer, sponsored by Fujirebio Diagnostics.

Completed
Registry status
130
Enrollment target
3
Study locations

NCT02270931 is a study of Breast Cancer that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 130 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02270931, a study of Breast Cancer, has completed, sponsored by Fujirebio Diagnostics.

COMPLETED
Registry status
130 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

Conditions Studied

Interventions

  • DEVICE CA 15-3 Assay

Study Locations (3)

Florida

  • Jane Skelton, MD - Boca Raton
  • Broward Health Medical Center - Fort Lauderdale

North Carolina

  • New Hanover Regional Medical Center - Wilmington

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2014-05
Est. Completion 2021-06-30

Sponsor

Fujirebio Diagnostics

13 total trials

What the Registry Record Tells You About NCT02270931

The ClinicalTrials.gov registry entry for NCT02270931 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Fujirebio Diagnostics, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CA 15-3 Assay is the first listed.

NCT02270931 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02270931 about?

NCT02270931 is a clinical study titled "A Prospective Longitudinal Breast Cancer Study". The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

What is the current status of trial NCT02270931?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2014-05. Estimated completion is 2021-06-30.

What conditions does trial NCT02270931 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02270931?

The interventions under investigation include: CA 15-3 Assay (DEVICE).

Who is sponsoring clinical trial NCT02270931?

This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02270931 being conducted?

This trial has 3 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.